Connection

Eric Meissner to Hepacivirus

Back to Details
This is a "connection" page, showing publications Eric Meissner has written about Hepacivirus.
Eric Meissner
Connection Strength
3.514
Hepacivirus
  1. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.
    View in: PubMed
    Score: 0.677
  2. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis. 2018 08 31; 67(6):878-880.
    View in: PubMed
    Score: 0.579
  3. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. Liver Int. 2015 Feb; 35(2):295-6.
    View in: PubMed
    Score: 0.452
  4. IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014 Jun 01; 209(11):1700-4.
    View in: PubMed
    Score: 0.418
  5. Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center. South Med J. 2022 06; 115(6):352-357.
    View in: PubMed
    Score: 0.188
  6. Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. J Viral Hepat. 2021 11; 28(11):1614-1623.
    View in: PubMed
    Score: 0.178
  7. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res. 2017 08; 144:281-285.
    View in: PubMed
    Score: 0.133
  8. Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis. Hepatol Int. 2016 Nov; 10(6):937-946.
    View in: PubMed
    Score: 0.123
  9. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62.
    View in: PubMed
    Score: 0.120
  10. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.
    View in: PubMed
    Score: 0.116
  11. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.
    View in: PubMed
    Score: 0.113
  12. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015 Mar; 61(3):790-801.
    View in: PubMed
    Score: 0.113
  13. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014 Nov 04; 161(9):634-8.
    View in: PubMed
    Score: 0.111
  14. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11.
    View in: PubMed
    Score: 0.102
  15. IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol. 2017 12 01; 199(11):3808-3820.
    View in: PubMed
    Score: 0.034
  16. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
    View in: PubMed
    Score: 0.029
  17. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.